Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: An apparatus on a machine tool for machining workpieces, preferably for machining workpieces by removing material, is provided to control functions of the machine tool and to program and/or test the machining of workpieces and/or to test the machine tool itself. The apparatus is provided with at least one display unit and at least one input unit, whereby masks for displaying and/or for inputting, via the input unit, machine and/or control parameters are displayable on the display unit. A start matrix having a grid of fields, which are stored in a geometrically addressable manner and are preferably arranged in rows and columns, can be displayed on the display unit, the input unit which is separate from the display unit being able to be used to select each field via its geometrical position in the grid at which it is displayed on the display unit, and the assigned function being able to be immediately triggered or a mask being able to be immediately displayed on the display unit by activating a field.

Abstract: The present invention is related to pyridinyl acetonitriles as well as to pharmaceutical formulations containing such pyridinyl acetonitriles. Said pyridinyl acetonitriles are modulators of the protein kinase signalling pathways, particularly the one involving Glycogen Kinase Synthase 3 or JNK. The present invention is furthermore related to methods of preparing pyridinyl acetonitriles. X is a substituted or unsubstituted pyridinyl. G is an unsubstituted or substituted pyrimidinyl or triazinyl.

Abstract: The invention relates to compounds of formula I: wherein R1, R2, Ra, Rb, X have the meanings given in claim 16. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Abstract: The invention provides 2-carboxamide piperazine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.

Abstract: The invention provides novel arylamino N-heteroaryl MEK inhibitors of Formula (I): Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.

Abstract: The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 15. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Abstract: Nitro-compounds are hydrogenated with an activated Ni catalyst that has an average particle size (APS) less than 25 ?m and is doped with one or more elements from the list of Mg, Ce, Ti, V, Nb, Cr, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Pt, Cu, Ag, Au and Bi via its/their addition to the alloy before activation and/or doped with one or more elements from the list of Mg, Ce, Ti, V, Nb, Cr, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Ni, Cu, Ag, Au and Bi by their adsorption onto the surface of the activated catalyst.

Abstract: The invention provides novel arylamino N-heteroaryl MEK inhibitors of Formula (I): Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.

Abstract: Nitro-compounds are hydrogenated with an activated Ni catalyst whose Ni/Al alloy also contained one or more elements from the list of Cu, Ag and Au prior to activation. In combination with the Group IB elements mentioned above, this catalyst can also be doped with other elements via their addition to the Ni/Al alloy prior to activation and/or they can be adsorbed onto the surface of the catalyst either during or after the activation of the alloy. The suitable doping elements for the alloy prior to activation in combination with the group IB elements mentioned above are one or more of the elements from the list of Mg, Ti, Ce, Cr, V, Mo, W, Mn, Re, Fe, Co, Tr, Ru, Rh, Pd, Pt and Bi. The suitable doping elements that may be adsorbed onto the surface of the catalyst that was previously doped in the alloy prior to activation with the group IB elements mentioned above are one or more elements from the list Mg, Ca, Ba, Ti, Ce, V, Cr, Mo, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Pd, Pt, Ni, Cu, Ag, Au and Bi.

Abstract: The invention provides 2-carboxamide piperazine compounds of formula I, R3.IN\?N˜?R2I(0)z-oR4I wherein R?, R2, R3 and R4 are as defined in the claims and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.

Abstract: Nitro-compounds are hydrogenated with an activated Ni catalyst that is doped during and/or after activation with one or more elements from the list of Mg, Ca, Ba, Ti, Zr, Ce, Nb, Cr, Mo, W, Mn, Re, Fe, Co, Ir, Ni, Cu, Ag, Au, Rh, Ru and Bi whereas the Ni/Al alloy may not, but preferentially can contain prior to activation one or more doping elements from the list of Ti, Ce, V, Cr, Mo, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Pd, Pt and Bi. If the Ni/Al alloy contained one or more of the above mentioned suitable alloy doping elements prior to activation, the resulting catalyst can then be doped with one or more of the elements from the list of Mg, Ca, Ba, Ti, Zr, Ce, V, Nb, Cr, Mo, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au and Bi by their adsorption onto the surface of the catalyst.

Abstract: Methods, systems, and apparatus, including computer program products, for implementing a software architecture design for a software application implementing service request and order management. The application is structured as multiple process components interacting with each other through service interfaces, and multiple service operations, each being implemented for a respective process component. The process components include an Outbound Delivery process component, a Site Logistics Processing process component, an Inventory Processing process component, a Customer Requirement Processing process component, a Supply and Demand Matching process component, a Logistics Execution Control process component, a Service Request Processing process component, a Service Order Processing process component, and a Service Confirmation Processing process component.

Abstract: Methods and apparatus, including systems and computer program products, for a services architecture design that provides enterprise services having customer relationship management functionality at the level of an enterprise application. The design includes a set of service operations, process components, and optionally deployment units. Suitable business objects are also described.

Abstract: The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the modulation of CRTH2 activity.

Abstract: The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.

Abstract: The present invention relates to novel pyrrolidine derivatives of Formula (I), its geometrical isomers, its optically active forms as enantiomers, diastercomers, mixtures of these and its racemate forms, as well as salts thereof, wherein: R1is selected from the group comprising or consisting of H and C1-C6-alkyl; R2 is selected from the group comprising or consisting of hydrogen, C1-C6-alkyl, C1-C6 alkyl aryl, heteroaryl, C1-C6 alkyl heteroaryl, C2-C6-alkenyl, C2-C6-alkenyl aryl, C2-C6 alkenyl heteroaryl, C2-C6-alkynyl, C2-C6-alkynyl aryl, C2C6-alkynyl heteroaryl, C3-C8 cycloalkyl, heterocycloalkyl, CI-C6-alkyl cycloallcyl, CI-C6-alkyl heterocycloalkyl, CIC6 alkyl carboxy, acyl, C1-C6-alkyl acyl, C1-C6-alkyl acyloxy, C1-C6-alkyl alkoxy, alkoxycarbonyl, C1-C6-alkyl alkoxycarbonyl, aminocarbonyl, C1-C6-alkyl aminocarbonyl, C1-C6-alkyl acylarnino, C1-C6-alkyl ureido, amino, C1-C6-alkyl amino, sulfonyloxy, C1-C6 alkyl sulfonyloxy, sulfonyl, C1-C6-alkyl sulfonyl, sulfinyl, C1-C6-alkyl sulfinyl, C1-C6alkyl sulfanyl

Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Abstract: The present invention is related to the use of 2,3 substituted pyrazine sulfonamides of formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of 2,3 substituted pyrazine sulfonamides for the modulation, notably the inhibition, of CRTH2 activity.